Catalio Capital Management LP Purchases Shares of 201,301 Fulcrum Therapeutics, Inc. $FULC

Catalio Capital Management LP purchased a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) in the fourth quarter, HoldingsChannel reports. The fund purchased 201,301 shares of the company’s stock, valued at approximately $2,277,000.

Other hedge funds have also recently bought and sold shares of the company. Aberdeen Group plc raised its stake in shares of Fulcrum Therapeutics by 135.0% in the 3rd quarter. Aberdeen Group plc now owns 137,961 shares of the company’s stock valued at $1,269,000 after buying an additional 79,265 shares in the last quarter. Braidwell LP acquired a new stake in shares of Fulcrum Therapeutics during the 3rd quarter worth about $2,019,000. Boothbay Fund Management LLC increased its position in Fulcrum Therapeutics by 104.2% in the 3rd quarter. Boothbay Fund Management LLC now owns 678,414 shares of the company’s stock valued at $6,241,000 after acquiring an additional 346,136 shares in the last quarter. Suvretta Capital Management LLC increased its position in Fulcrum Therapeutics by 5.9% in the 3rd quarter. Suvretta Capital Management LLC now owns 5,381,000 shares of the company’s stock valued at $49,505,000 after acquiring an additional 298,100 shares in the last quarter. Finally, GSA Capital Partners LLP increased its position in Fulcrum Therapeutics by 256.4% in the 3rd quarter. GSA Capital Partners LLP now owns 116,068 shares of the company’s stock valued at $1,068,000 after acquiring an additional 83,505 shares in the last quarter. 89.83% of the stock is owned by institutional investors.

Fulcrum Therapeutics Price Performance

FULC stock opened at $3.50 on Thursday. The company has a fifty day moving average price of $6.32 and a two-hundred day moving average price of $8.63. The stock has a market cap of $233.21 million, a price-to-earnings ratio of -3.04 and a beta of 2.93. Fulcrum Therapeutics, Inc. has a one year low of $2.83 and a one year high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its earnings results on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.06. Research analysts anticipate that Fulcrum Therapeutics, Inc. will post -0.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on FULC shares. Truist Financial lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 target price on the stock. in a research note on Tuesday, June 2nd. Cantor Fitzgerald lowered shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Leerink Partners downgraded shares of Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 target price on the stock. in a report on Tuesday, June 2nd. Stifel Nicolaus downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price objective on the stock. in a report on Tuesday, June 2nd. Finally, Wall Street Zen upgraded shares of Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 2nd. One research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $8.20.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.